A Double-Blind, Randomized, Crossover, Through QT/QTc Trial to Evaluate the Potential of Deferiprone to Prolong the QT Interval in Healthy Subjects

Trial Profile

A Double-Blind, Randomized, Crossover, Through QT/QTc Trial to Evaluate the Potential of Deferiprone to Prolong the QT Interval in Healthy Subjects

Completed
Phase of Trial: Phase IV

Latest Information Update: 01 Jan 2017

At a glance

  • Drugs Deferiprone (Primary) ; Moxifloxacin
  • Indications Friedreich's ataxia; HIV infections; Iron overload; Kidney disorders; Pantothenate kinase-associated neurodegeneration
  • Focus Adverse reactions
  • Sponsors ApoPharma
  • Most Recent Events

    • 04 Jun 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top